Neurocrine Biosciences' (NBIX) Ingrezza should at least meet the company's fiscal 2025 sales guidance due to an expected re-acceleration in new patient starts and as payer-related headwinds are unlikely to have an impact in Q2 and Q3, RBC Capital Markets said in a Monday note.
Ingrezza is a treatment for adults with tardive dyskinesia and for involuntary movements of Huntington's disease.
The company said last month it expects Ingrezza fiscal 2025 sales of $2.5 billion to $2.6 billion.
RBC said its formulary and prescription checks indicate "some favorable updates and stable coverage into Q2/Q3."
According to the investment firm, its checks reaffirmed a "solid" outlook for Ingrezza for the rest of 2025 with stabilizing coverage access.
In addition, market uptake for the company's Crenessity drug serves as a potential catalyst that could sustain stock momentum, RBC said.
RBC has an outperform rating on Neurocrine Biosciences, with a $145 price target.
Price: 123.03, Change: +0.01, Percent Change: +0.01
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。